{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:55:47Z","timestamp":1790218547318,"version":"4.1.0"},"reference-count":178,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":374,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB-1470-A07"],"award-info":[{"award-number":["SFB-1470-A07"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["536819681"],"award-info":[{"award-number":["536819681"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70115119"],"award-info":[{"award-number":["70115119"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","award":["ERC CoG 101045236"],"award-info":[{"award-number":["ERC CoG 101045236"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","award":["DISSECT-HF"],"award-info":[{"award-number":["DISSECT-HF"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["CRC1366 C07"],"award-info":[{"award-number":["CRC1366 C07"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["394046768"],"award-info":[{"award-number":["394046768"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union's Horizon 2020 research and innovation programme","award":["759248"],"award-info":[{"award-number":["759248"]}]},{"name":"Health+Life Science Alliance Heidelberg Mannheim GmbH"},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/CRTF\/21\/24175"],"award-info":[{"award-number":["FS\/CRTF\/21\/24175"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"name":"King's College London BHF Centre of Research Excellence","award":["RE\/18\/2\/34213"],"award-info":[{"award-number":["RE\/18\/2\/34213"]}]},{"name":"European Commission Horizon 2020 programme","award":["825670"],"award-info":[{"award-number":["825670"]}]},{"name":"European Commission Horizon 2020 programme","award":["874764"],"award-info":[{"award-number":["874764"]}]},{"name":"German Federal Ministry of Education and Research"},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CIBERCV CB16\/11\/00483"],"award-info":[{"award-number":["CIBERCV CB16\/11\/00483"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/00946"],"award-info":[{"award-number":["PI21\/00946"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norwegian Research council","doi-asserted-by":"publisher","award":["#309762"],"award-info":[{"award-number":["#309762"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010447","name":"German Center for Cardiovascular Research","doi-asserted-by":"publisher","award":["81Z0500101 and 81X2500195"],"award-info":[{"award-number":["81Z0500101 and 81X2500195"]}],"id":[{"id":"10.13039\/100010447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010447","name":"German Center for Cardiovascular Research","doi-asserted-by":"publisher","award":["DZHK-BHF: 81X2600522"],"award-info":[{"award-number":["DZHK-BHF: 81X2600522"]}],"id":[{"id":"10.13039\/100010447","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bavarian State Ministry of Health","award":["DMB-1805\u20130001"],"award-info":[{"award-number":["DMB-1805\u20130001"]}]},{"name":"Bavarian State Ministry of Science and the Arts","award":["1530\/89102"],"award-info":[{"award-number":["1530\/89102"]}]},{"name":"German Federal Ministry of Economics and Energy"},{"name":"German Federal Ministry of Education and Research","award":["ZF4590201BA8"],"award-info":[{"award-number":["ZF4590201BA8"]}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Leducq Foundation for Cardiovascular Research","award":["20CVD01"],"award-info":[{"award-number":["20CVD01"]}]},{"name":"Leducq Foundation for Cardiovascular Research","award":["18CVD02"],"award-info":[{"award-number":["18CVD02"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["471241922"],"award-info":[{"award-number":["471241922"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RTG2824-RP4"],"award-info":[{"award-number":["RTG2824-RP4"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB-1470-B02"],"award-info":[{"award-number":["SFB-1470-B02"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1366-C07"],"award-info":[{"award-number":["SFB1366-C07"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["394046768"],"award-info":[{"award-number":["394046768"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","award":["PNRR-MAD-2022-12376632"],"award-info":[{"award-number":["PNRR-MAD-2022-12376632"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","award":["RF-2016-02362988"],"award-info":[{"award-number":["RF-2016-02362988"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union Commission's Seventh Framework programme IMI2-CARDIATEAM","award":["N\u00b0 821508"],"award-info":[{"award-number":["N\u00b0 821508"]}]},{"DOI":"10.13039\/501100002996","name":"Dutch Heart Foundation","doi-asserted-by":"crossref","award":["2020-B005"],"award-info":[{"award-number":["2020-B005"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union's Horizon 2020 research and innovation programme"},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB\u20101470\u2010A07"],"award-info":[{"award-number":["SFB\u20101470\u2010A07"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["536819681"],"award-info":[{"award-number":["536819681"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70115119"],"award-info":[{"award-number":["70115119"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["ERC CoG 101045236"],"award-info":[{"award-number":["ERC CoG 101045236"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["DISSECT\u2010HF"],"award-info":[{"award-number":["DISSECT\u2010HF"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 Excellent Science - European Research Council","doi-asserted-by":"publisher","award":["759248"],"award-info":[{"award-number":["759248"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/CRTF\/21\/24175"],"award-info":[{"award-number":["FS\/CRTF\/21\/24175"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010447","name":"Deutsches Zentrum f\u00fcr Herz-Kreislaufforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CIBERCV CB16\/11\/00483"],"award-info":[{"award-number":["CIBERCV CB16\/11\/00483"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/00946"],"award-info":[{"award-number":["PI21\/00946"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["#309762"],"award-info":[{"award-number":["#309762"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNRR\u2010MAD\u20102022\u201012376632"],"award-info":[{"award-number":["PNRR\u2010MAD\u20102022\u201012376632"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF\u20102016\u201002362988"],"award-info":[{"award-number":["RF\u20102016\u201002362988"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gene therapy has recently become a reality in the treatment of cardiovascular diseases. Strategies to modulate gene expression using antisense oligonucleotides or small interfering RNA are proving to be safe and effective in the clinic. Adeno-associated viral vector-based gene delivery and CRISPR-Cas9-based genome editing have emerged as efficient strategies for gene delivery and repair in humans. Overall, gene therapy holds the promise not only of expanding current treatment options, but also of intervening in previously untackled causal disease mechanisms with little side effects. This scientific statement provides a comprehensive overview of the various modalities of gene therapy used to treat heart failure and some of its risk factors, and their application in the clinical setting. It discusses specifically the possibilities of gene therapy for hereditary heart diseases and (non)-genetic heart failure. Furthermore, it addresses safety and clinical trial design issues and challenges for future regulatory strategies.<\/jats:p>","DOI":"10.1002\/ejhf.3516","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T10:34:12Z","timestamp":1732271652000},"page":"5-25","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["State of the Art and Perspectives of Gene Therapy in Heart Failure. A Scientific Statement of the Heart Failure Association of the ESC, the ESC Council on Cardiovascular Genomics and the ESC Working Group on Myocardial &amp; Pericardial Diseases"],"prefix":"10.1093","volume":"27","author":[{"given":"Sophie","family":"Van Linthout","sequence":"first","affiliation":[{"name":"Berlin Institute of Health (BIH) at Charit\u00e9 \u2013 Universit\u00e4tmedizin Berlin, BIH Center for Regenerative Therapies (BCRT) , Berlin ,","place":["Germany"]},{"name":"German Center for Cardiovascular Research (DZHK), partner site Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Stellos","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Research, Medical Faculty Mannheim, Heidelberg University , Mannheim ,","place":["Germany"]},{"name":"Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Heidelberg University , Mannheim ,","place":["Germany"]},{"name":"German Centre for Cardiovascular Research (DZHK), partner site Heidelberg\/Mannheim , Mannheim ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Giacca","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Medicine & Sciences and British Heart Foundation Centre of Research Excellence, King's College London, London, UK; Department of Medical Sciences, University of Trieste , Trieste ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Bertero","sequence":"additional","affiliation":[{"name":"Cardiovascular Unit, Department of Internal Medicine, University of Genova , Genova ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cannata","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Medicine & Sciences and British Heart Foundation Centre of Research Excellence, King's College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Carrier","sequence":"additional","affiliation":[{"name":"Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf , Hamburg ,","place":["Germany"]},{"name":"German Centre for Cardiovascular Research (DZHK), partner site Hamburg\/Kiel\/L\u00fcbeck , Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV , Madrid ,","place":["Spain"]},{"name":"Centro Nacional de Investigaciones Cardiovasculares (CNIC) , Madrid ,","place":["Spain"]},{"name":"Universidad Francisco de Vitoria (UFV) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ghigo","sequence":"additional","affiliation":[{"name":"Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center \"Guido Tarone,\" University of Torino , Torino ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantxa","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Program of Cardiovascular Diseases, CIMA and Department of Pathology, Anatomy and Physiology, Universidad de Navarra , Pamplona ,","place":["Spain"]},{"name":"IdiSNA, Navarra Institute for Health Research , Pamplona ,","place":["Spain"]},{"name":"CIBERCV (Network for Biomedical Research in Cardiovascular Disease), Instituto de Salud Carlos II , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina H.","family":"Haugaa","sequence":"additional","affiliation":[{"name":"ProCardio Center for Innovation, Department of Cardiology, Oslo University Hospital, Rikshospitalet , Oslo ,","place":["Norway"]},{"name":"Faculty of Medicine, Institute of Clinical Medicine, University of Oslo , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Imazio","sequence":"additional","affiliation":[{"name":"Department of Medicine (DMED), University of Udine, and Cardiothoracic Department ASUFC, University Hospital Santa Maria della Misericordia , Udine ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis R.","family":"Lopes","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Science, University College London , London ,","place":["UK"]},{"name":"Barts Heart Centre, St Bartholomew's Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Most","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology, Pulmonology, University Hospital Heidelberg , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Pollesello","sequence":"additional","affiliation":[{"name":"Content and Communication, Branded Products , Espoo ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heribert","family":"Schunkert","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Deutsches Herzzentrum M\u00fcnchen, Technische Universit\u00e4t M\u00fcnchen , Munich ,","place":["Germany"]},{"name":"German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Streckfuss-B\u00f6meke","sequence":"additional","affiliation":[{"name":"Clinic for Cardiology and Pneumology, University Medical Center , G\u00f6ttingen ,","place":["Germany"]},{"name":"German Center for Cardiovascular Research (DZHK), Partner site G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]},{"name":"Institute of Pharmacology and Toxicology, University of W\u00fcrzburg , W\u00fcrzburg ,","place":["Germany"]},{"name":"Department of Translational Research, Comprehensive Heart Failure Center (CHFC), University Clinic W\u00fcrzburg , W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Thum","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Gabriele","family":"Tocchetti","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences; Center for Basic and Clinical Immunology Research (CISI); Interdepartmental Center for Clinical and Translational Research (CIRCET); Interdepartmental Hypertension Research Center (CIRIAPA), Federico II University , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Tsch\u00f6pe","sequence":"additional","affiliation":[{"name":"Berlin Institute of Health (BIH) at Charit\u00e9 \u2013 Universit\u00e4tmedizin Berlin, BIH Center for Regenerative Therapies (BCRT) , Berlin ,","place":["Germany"]},{"name":"German Center for Cardiovascular Research (DZHK), partner site Berlin , Berlin ,","place":["Germany"]},{"name":"Deutsches Herzzentrum der Charit\u00e9 (DHZC), Department of Cardiology, Angiology and Intensive Medicine, Campus Virchow Klinikum , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van der Meer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Groningen, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"van Rooij","sequence":"additional","affiliation":[{"name":"Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]},{"name":"Department of Cardiology, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe M.C.","family":"Rosano","sequence":"additional","affiliation":[{"name":"Cardiovascular Clinical Academic Group, St. George's University Hospitals, NHS Trust, University of London , London ,","place":["UK"]},{"name":"Cardiology, San Raffaele Cassino Hospital , Cassino ,","place":["Italy"]},{"name":"Department of Human Sciences and Promotion of Quality of Life, San Raffaele University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Heymans","sequence":"additional","affiliation":[{"name":"Centre for Molecular and Vascular Biology, KU Leuven , Leuven ,","place":["Belgium"]},{"name":"Department of Cardiology, Maastricht University, CARIM School for Cardiovascular Diseases , Maastricht ,","place":["The Netherlands"]},{"name":"European Reference Network for Rare Low Prevalence and Complex Diseases of the Heart (ERN GUARD-Heart) , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"key":"2026080801403490600_ejhf3516-bib-0001","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.175.4025.949","article-title":"Gene therapy for human genetic disease?","volume":"175","author":"Friedmann","year":"1972","journal-title":"Science"},{"key":"2026080801403490600_ejhf3516-bib-0002","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1161\/CIRCRESAHA.122.320496","article-title":"CRISPR modeling and correction of cardiovascular disease","volume":"130","author":"Liu","year":"2022","journal-title":"Circ Res"},{"key":"2026080801403490600_ejhf3516-bib-0003","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrd3864","article-title":"MicroRNA therapeutics for cardiovascular disease: Opportunities and obstacles","volume":"11","author":"van Rooij","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"2026080801403490600_ejhf3516-bib-0004","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/stcltm\/szad038","article-title":"Fulfilling the promise of RNA therapies for cardiac repair and regeneration","volume":"12","author":"Giacca","year":"2023","journal-title":"Stem Cells Transl Med"},{"key":"2026080801403490600_ejhf3516-bib-0005","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1093\/eurheartj\/ehac463","article-title":"Small non-coding RNA therapeutics for cardiovascular disease","volume":"43","author":"Shah","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080801403490600_ejhf3516-bib-0006","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2026080801403490600_ejhf3516-bib-0007","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/nat.2018.0721","article-title":"Lipid nanoparticles enabling gene therapies: From concepts to clinical utility","volume":"28","author":"Kulkarni","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"2026080801403490600_ejhf3516-bib-0008","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080801403490600_ejhf3516-bib-0009","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.jacc.2017.08.009","article-title":"Genetically confirmed familial hypercholesterolemia in patients with acute coronary syndrome","volume":"70","author":"Amor-Salamanca","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026080801403490600_ejhf3516-bib-0010","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2208391","article-title":"Zilebesiran, an RNA interference therapeutic agent for hypertension","volume":"389","author":"Desai","year":"2023","journal-title":"N Engl J Med"},{"key":"2026080801403490600_ejhf3516-bib-0011","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"2026080801403490600_ejhf3516-bib-0012","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"2026080801403490600_ejhf3516-bib-0013","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cardfail.2009.01.013","article-title":"Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID trial), a first-in-human phase 1\/2 clinical trial","volume":"15","author":"Jaski","year":"2009","journal-title":"J Card Fail"},{"key":"2026080801403490600_ejhf3516-bib-0014","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","article-title":"Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure","volume":"124","author":"Jessup","year":"2011","journal-title":"Circulation"},{"key":"2026080801403490600_ejhf3516-bib-0015","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/ejhf.826","article-title":"Effect of intracoronary administration of AAV1\/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: Results from the AGENT-HF randomized phase 2 trial","volume":"19","author":"Hulot","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026080801403490600_ejhf3516-bib-0016","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/path.2993","article-title":"Silencing disease genes in the laboratory and the clinic","volume":"226","author":"Watts","year":"2012","journal-title":"J Pathol"},{"key":"2026080801403490600_ejhf3516-bib-0017","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/gt.2011.100","article-title":"Chemical modification and design of anti-miRNA oligonucleotides","volume":"18","author":"Lennox","year":"2011","journal-title":"Gene Ther"},{"key":"2026080801403490600_ejhf3516-bib-0018","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9062004","article-title":"Antisense oligonucleotides: An emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J Clin Med"},{"key":"2026080801403490600_ejhf3516-bib-0019","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1152\/physrev.00041.2015","article-title":"Non-coding RNAs in development and disease: Background, mechanisms, and therapeutic approaches","volume":"96","author":"Beermann","year":"2016","journal-title":"Physiol Rev"},{"key":"2026080801403490600_ejhf3516-bib-0020","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/eurheartj\/ehaa870","article-title":"CDR132L: Another brick in the wall towards the use of miRNAs to treat cardiovascular disease","volume":"42","author":"Devaux","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080801403490600_ejhf3516-bib-0021","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/CIRCRESAHA.116.309589","article-title":"Single-dose intracardiac injection of pro-regenerative microRNAs improves cardiac function after myocardial infarction","volume":"120","author":"Lesizza","year":"2017","journal-title":"Circ Res"},{"key":"2026080801403490600_ejhf3516-bib-0022","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1038\/s41467-019-09530-1","article-title":"Therapeutic role of miR-19a\/19b in cardiac regeneration and protection from myocardial infarction","volume":"10","author":"Gao","year":"2019","journal-title":"Nat Commun"},{"key":"2026080801403490600_ejhf3516-bib-0023","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010841","article-title":"A microRNA-Hippo pathway that promotes cardiomyocyte proliferation and cardiac regeneration in mice","volume":"7","author":"Tian","year":"2015","journal-title":"Sci Transl Med"},{"key":"2026080801403490600_ejhf3516-bib-0024","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.7150\/thno.16478","article-title":"Neonatal heart-enriched miR-708 promotes proliferation and stress resistance of cardiomyocytes in rodents","volume":"7","author":"Deng","year":"2017","journal-title":"Theranostics"},{"key":"2026080801403490600_ejhf3516-bib-0025","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Kariko","year":"2008","journal-title":"Mol Ther"},{"key":"2026080801403490600_ejhf3516-bib-0026","article-title":"Cap 1 messenger RNA synthesis with co-transcriptional CleanCap\u00ae analog by in vitro transcription","volume":"1","author":"Henderson","year":"2021","journal-title":"Curr Protoc"},{"key":"2026080801403490600_ejhf3516-bib-0027","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics \u2013 developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"2026080801403490600_ejhf3516-bib-0028","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.addr.2020.10.014","article-title":"Recent advances in chemical modifications of guide RNA, mRNA and donor template for CRISPR-mediated genome editing","volume":"168","author":"Chen","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"2026080801403490600_ejhf3516-bib-0029","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415514","article-title":"Modified mRNA therapeutics for heart diseases","volume":"23","author":"Magadum","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026080801403490600_ejhf3516-bib-0030","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ymthe.2018.11.018","article-title":"mRNA-based protein replacement therapy for the heart","volume":"27","author":"Magadum","year":"2019","journal-title":"Mol Ther"},{"key":"2026080801403490600_ejhf3516-bib-0031","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s10557-020-07051-4","article-title":"Modified mRNA as a therapeutic tool for the heart","volume":"34","author":"Kaur","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026080801403490600_ejhf3516-bib-0032","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.omtn.2018.08.021","article-title":"Ablation of a single N-glycosylation site in human FSTL 1 induces cardiomyocyte proliferation and cardiac regeneration","volume":"13","author":"Magadum","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026080801403490600_ejhf3516-bib-0033","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1161\/CIRCULATIONAHA.119.043067","article-title":"Pkm2 regulates cardiomyocyte cell cycle and promotes cardiac regeneration","volume":"141","author":"Magadum","year":"2020","journal-title":"Circulation"},{"key":"2026080801403490600_ejhf3516-bib-0034","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201900424","article-title":"aYAP modRNA reduces cardiac inflammation and hypertrophy in a murine ischemia-reperfusion model","volume":"3","author":"Chen","year":"2020","journal-title":"Life Sci Alliance"},{"key":"2026080801403490600_ejhf3516-bib-0035","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1161\/CIRCULATIONAHA.119.041882","article-title":"Altering sphingolipid metabolism attenuates cell death and inflammatory response after myocardial infarction","volume":"141","author":"Hadas","year":"2020","journal-title":"Circulation"},{"key":"2026080801403490600_ejhf3516-bib-0036","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1021\/mp5006239","article-title":"Synthetic chemically modified mrna-based delivery of cytoprotective factor promotes early cardiomyocyte survival post-acute myocardial infarction","volume":"12","author":"Huang","year":"2015","journal-title":"Mol Pharm"},{"key":"2026080801403490600_ejhf3516-bib-0037","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/nbt.2682","article-title":"Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction","volume":"31","author":"Zangi","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2026080801403490600_ejhf3516-bib-0038","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.omtm.2018.04.003","article-title":"Biocompatible, purified VEGF-A mRNA improves cardiac function after intracardiac injection 1 week post-myocardial infarction in swine","volume":"9","author":"Carlsson","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2026080801403490600_ejhf3516-bib-0039","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"2026080801403490600_ejhf3516-bib-0040","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.3779","article-title":"Cellular uptake and trafficking of antisense oligonucleotides","volume":"35","author":"Crooke","year":"2017","journal-title":"Nat Biotechnol"},{"key":"2026080801403490600_ejhf3516-bib-0041","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"2026080801403490600_ejhf3516-bib-0042","first-page":"252","article-title":"Progress towards a synthetic virus for systemic gene therapy","volume":"1","author":"MacLachlan","year":"1999","journal-title":"Curr Opin Mol Ther"},{"key":"2026080801403490600_ejhf3516-bib-0043","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jconrel.2005.06.014","article-title":"Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids","volume":"107","author":"Heyes","year":"2005","journal-title":"J Control Release"},{"key":"2026080801403490600_ejhf3516-bib-0044","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1089\/hum.2017.172","article-title":"Small but increasingly mighty: Latest advances in AAV vector research, design, and evolution","volume":"28","author":"Grimm","year":"2017","journal-title":"Hum Gene Ther"},{"key":"2026080801403490600_ejhf3516-bib-0045","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/nbt856","article-title":"Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors","volume":"21","author":"Muller","year":"2003","journal-title":"Nat Biotechnol"},{"key":"2026080801403490600_ejhf3516-bib-0046","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gt.2011.143","article-title":"Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors","volume":"19","author":"Varadi","year":"2012","journal-title":"Gene Ther"},{"key":"2026080801403490600_ejhf3516-bib-0047","first-page":"441","article-title":"Engineered adeno-associated viral vectors with animproved in vivo targeting of cardiac fibroblasts","volume":"25","author":"Gro\u00df","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080801403490600_ejhf3516-bib-0048","doi-asserted-by":"crossref","first-page":"10553","DOI":"10.1038\/s41598-021-89989-5","article-title":"AAV-mediated YAP expression in cardiac fibroblasts promotes inflammation and increases fibrosis","volume":"11","author":"Francisco","year":"2021","journal-title":"Sci Rep"},{"key":"2026080801403490600_ejhf3516-bib-0049","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41569-022-00799-2","article-title":"Cardiac fibroblasts and mechanosensation in heart development, health and disease","volume":"20","author":"Pesce","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2026080801403490600_ejhf3516-bib-0050","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1161\/CIRCIMAGING.112.000320","article-title":"Cardiac-selective expression of extracellular superoxide dismutase after systemic injection of adeno-associated virus 9 protects the heart against post-myocardial infarction left ventricular remodeling","volume":"6","author":"Konkalmatt","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026080801403490600_ejhf3516-bib-0051","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1182\/blood.V86.5.1828.bloodjournal8651828","article-title":"Endothelial-specific gene expression directed by the tie gene promoter in vivo","volume":"86","author":"Korhonen","year":"1995","journal-title":"Blood"},{"key":"2026080801403490600_ejhf3516-bib-0052","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"2026080801403490600_ejhf3516-bib-0053","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: precision chemistry on the genome and transcriptome of living cells","volume":"19","author":"Rees","year":"2018","journal-title":"Nat Rev Genet"},{"key":"2026080801403490600_ejhf3516-bib-0054","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.ade1105","article-title":"Ablation of CaMKIIdelta oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease","volume":"379","author":"Lebek","year":"2023","journal-title":"Science"},{"key":"2026080801403490600_ejhf3516-bib-0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"2026080801403490600_ejhf3516-bib-0056","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080801403490600_ejhf3516-bib-0057","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N Engl J Med"},{"key":"2026080801403490600_ejhf3516-bib-0058","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ejhf.2783","article-title":"Effect of patisiran on stroke volume in hereditary transthyretin-mediated amyloidosis: Insights from pressure-volume analysis of the APOLLO study","volume":"25","author":"Rosenblum","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080801403490600_ejhf3516-bib-0059","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"2026080801403490600_ejhf3516-bib-0060","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"2026080801403490600_ejhf3516-bib-0061","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: A randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"2026080801403490600_ejhf3516-bib-0062","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ejhf.3138","article-title":"Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"26","author":"Garcia-Pavia","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026080801403490600_ejhf3516-bib-0063","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","author":"Fontana","year":"2024","journal-title":"N Engl J Med"},{"key":"2026080801403490600_ejhf3516-bib-0064","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080801403490600_ejhf3516-bib-0065","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","article-title":"Inclisiran and cardiovascular events: A patient-level analysis of phase III trials","volume":"44","author":"Ray","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080801403490600_ejhf3516-bib-0066","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026080801403490600_ejhf3516-bib-0067","doi-asserted-by":"publisher","first-page":"A15751","DOI":"10.1161\/circ.142.suppl_3.15751","article-title":"Pharmacodynamic effect of ARO-ANG3, an investigational RNA interference targeting hepatic angiopoietin-like protein 3, in patients with hypercholesterolemia","volume":"142","author":"Watts","year":"2020","journal-title":"Circulation"},{"key":"2026080801403490600_ejhf3516-bib-0068","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Emerging Risk Factors","year":"2009","journal-title":"JAMA"},{"key":"2026080801403490600_ejhf3516-bib-0069","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/17512433.2023.2277330","article-title":"Emerging insights and future prospects for therapeutic application of siRNA targeting angiotensinogen in hypertension","volume":"16","author":"Addison","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026080801403490600_ejhf3516-bib-0070","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"2026080801403490600_ejhf3516-bib-0071","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","article-title":"Inotersen therapy of transthyretin amyloid cardiomyopathy","volume":"27","author":"Dasgupta","year":"2020","journal-title":"Amyloid"},{"key":"2026080801403490600_ejhf3516-bib-0072","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"2026080801403490600_ejhf3516-bib-0073","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2023.11.016","article-title":"Effect of eplontersen on cardiac structure and function in patients with hereditary transthyretin amyloidosis","volume":"30","author":"Masri","year":"2024","journal-title":"J Card Fail"},{"key":"2026080801403490600_ejhf3516-bib-0074","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159179","article-title":"MicroRNAs as therapeutic targets in cardiovascular disease","volume":"132","author":"Laggerbauer","year":"2022","journal-title":"J Clin Invest"},{"key":"2026080801403490600_ejhf3516-bib-0075","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1161\/CIRCRESAHA.119.315856","article-title":"Preclinical and clinical development of noncoding RNA therapeutics for cardiovascular disease","volume":"126","author":"Huang","year":"2020","journal-title":"Circ Res"},{"key":"2026080801403490600_ejhf3516-bib-0076","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/ncomms2090","article-title":"The miRNA-212\/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy","volume":"3","author":"Ucar","year":"2012","journal-title":"Nat Commun"},{"key":"2026080801403490600_ejhf3516-bib-0077","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41467-020-14349-2","article-title":"Preclinical development of a miR-132 inhibitor for heart failure treatment","volume":"11","author":"Foinquinos","year":"2020","journal-title":"Nat Commun"},{"key":"2026080801403490600_ejhf3516-bib-0078","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehaa791","article-title":"CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure","volume":"42","author":"Batkai","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080801403490600_ejhf3516-bib-0079","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/eurheartj\/ehaa898","article-title":"Novel antisense therapy targeting microRNA-132 in patients with heart failure: Results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study","volume":"42","author":"Taubel","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080801403490600_ejhf3516-bib-0080","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/ejhf.3139","article-title":"Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF-REVERT trial","volume":"26","author":"Bauersachs","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026080801403490600_ejhf3516-bib-0081","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41573-021-00355-6","article-title":"VEGFA mRNA for regenerative treatment of heart failure","volume":"21","author":"Collen","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"2026080801403490600_ejhf3516-bib-0082","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/s41467-019-08852-4","article-title":"Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes","volume":"10","author":"Gan","year":"2019","journal-title":"Nat Commun"},{"key":"2026080801403490600_ejhf3516-bib-0083","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ymthe.2022.11.017","article-title":"Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting","volume":"31","author":"Anttila","year":"2023","journal-title":"Mol Ther"},{"key":"2026080801403490600_ejhf3516-bib-0084","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1161\/CIRCRESAHA.111.259754","article-title":"Modulation of cardiac contractility by the phospholamban\/SERCA2a regulatome","volume":"110","author":"Kranias","year":"2012","journal-title":"Circ Res"},{"key":"2026080801403490600_ejhf3516-bib-0085","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium Upregulation by Percutaneous Administration of Gene Therapy in Patients with Cardiac Disease (CUPID 2): A randomised, multinational, double-blind, placebo-controlled, phase 2b trial","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet"},{"key":"2026080801403490600_ejhf3516-bib-0086","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1161\/CIRCRESAHA.120.315855","article-title":"Gene therapy for the heart lessons learned and future perspectives","volume":"126","author":"Cannata","year":"2020","journal-title":"Circ Res"},{"key":"2026080801403490600_ejhf3516-bib-0087","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/CIRCULATIONAHA.123.064513","article-title":"SERCA2a protein levels are unaltered in human heart failure","volume":"148","author":"Ragone","year":"2023","journal-title":"Circulation"},{"key":"2026080801403490600_ejhf3516-bib-0088","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41434-020-0171-7","article-title":"Investigation of the safety and feasibility of AAV1\/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device \u2013 the SERCA-LVAD trial","volume":"27","author":"Lyon","year":"2020","journal-title":"Gene Ther"},{"key":"2026080801403490600_ejhf3516-bib-0089","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/mt.2014.127","article-title":"Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure","volume":"22","author":"Ishikawa","year":"2014","journal-title":"Mol Ther"},{"key":"2026080801403490600_ejhf3516-bib-0090","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/01.RES.0000161256.85833.fa","article-title":"Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1","volume":"96","author":"Pathak","year":"2005","journal-title":"Circ Res"},{"key":"2026080801403490600_ejhf3516-bib-0091","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/jpn3.12326","article-title":"Adeno-associated viral vector gene therapy: Challenges for the paediatric hepatologist","volume":"79","author":"Jagadisan","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026080801403490600_ejhf3516-bib-0092","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/d41586-023-03590-6","article-title":"UK first to approve CRISPR treatment for diseases: What you need to know","volume":"623","author":"Wong","year":"2023","journal-title":"Nature"},{"key":"2026080801403490600_ejhf3516-bib-0093","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026080801403490600_ejhf3516-bib-0094","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1038\/d41591-022-00101-4","article-title":"CRISPR-Cas9 hits its target in amyloidosis","volume":"28","author":"Carvalho","year":"2022","journal-title":"Nat Med"},{"key":"2026080801403490600_ejhf3516-bib-0095","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","article-title":"In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels","volume":"39","author":"Rothgangl","year":"2021","journal-title":"Nat Biotechnol"},{"key":"2026080801403490600_ejhf3516-bib-0096","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"2026080801403490600_ejhf3516-bib-0097","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ejhf.1461","article-title":"Heart failure in cardiomyopathies: A position paper from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovic","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026080801403490600_ejhf3516-bib-0098","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080801403490600_ejhf3516-bib-0099","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(23)01241-2","article-title":"Dilated cardiomyopathy: Causes, mechanisms, and current and future treatment approaches","volume":"402","author":"Heymans","year":"2023","journal-title":"Lancet"},{"key":"2026080801403490600_ejhf3516-bib-0100","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080801403490600_ejhf3516-bib-0101","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2026080801403490600_ejhf3516-bib-0102","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1038\/s41467-021-25439-0","article-title":"Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy","volume":"12","author":"Grote Beverborg","year":"2021","journal-title":"Nat Commun"},{"key":"2026080801403490600_ejhf3516-bib-0103","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052427","article-title":"Antisense therapy attenuates phospholamban p.(Arg14del) cardiomyopathy in mice and reverses protein aggregation","volume":"23","author":"Eijgenraam","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026080801403490600_ejhf3516-bib-0104","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/emmm.201202168","article-title":"Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice","volume":"5","author":"Gedicke-Hornung","year":"2013","journal-title":"EMBO Mol Med"},{"key":"2026080801403490600_ejhf3516-bib-0105","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/science.1236921","article-title":"Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy","volume":"342","author":"Jiang","year":"2013","journal-title":"Science"},{"key":"2026080801403490600_ejhf3516-bib-0106","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/cvr\/cvp247","article-title":"The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy","volume":"85","author":"Carrier","year":"2010","journal-title":"Cardiovasc Res"},{"key":"2026080801403490600_ejhf3516-bib-0107","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/CIRCRESAHA.109.201251","article-title":"Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyopathic mice","volume":"105","author":"Vignier","year":"2009","journal-title":"Circ Res"},{"key":"2026080801403490600_ejhf3516-bib-0108","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.yjmcc.2020.10.003","article-title":"Targeting the population for gene therapy with MYBPC3","volume":"150","author":"Carrier","year":"2021","journal-title":"J Mol Cell Cardiol"},{"key":"2026080801403490600_ejhf3516-bib-0109","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJMoa1110186","article-title":"Truncations of titin causing dilated cardiomyopathy","volume":"366","author":"Herman","year":"2012","journal-title":"N Engl J Med"},{"key":"2026080801403490600_ejhf3516-bib-0110","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027373","article-title":"Genetics of BAG3: A paradigm for developing precision therapies for dilated cardiomyopathies","volume":"11","author":"Qu","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026080801403490600_ejhf3516-bib-0111","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/humu.24004","article-title":"A mutation update for the FLNC gene in myopathies and cardiomyopathies","volume":"41","author":"Verdonschot","year":"2020","journal-title":"Hum Mutat"},{"key":"2026080801403490600_ejhf3516-bib-0112","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.121.003672","article-title":"Variant location is a novel risk factor for individuals with arrhythmogenic cardiomyopathy due to a desmoplakin (DSP) truncating variant","volume":"16","author":"Hoorntje","year":"2023","journal-title":"Circ Genom Precis Med"},{"key":"2026080801403490600_ejhf3516-bib-0113","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41436-021-01233-7","article-title":"The genetic architecture of plakophilin 2 cardiomyopathy","volume":"23","author":"Dries","year":"2021","journal-title":"Genet Med"},{"key":"2026080801403490600_ejhf3516-bib-0114","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1038\/ncomms6515","article-title":"Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice","volume":"5","author":"Mearini","year":"2014","journal-title":"Nat Commun"},{"key":"2026080801403490600_ejhf3516-bib-0115","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.omtn.2017.05.008","article-title":"Evaluation of MYBPC3 trans-splicing and gene replacement as therapeutic options in human iPSC-derived cardiomyocytes","volume":"7","author":"Prondzynski","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026080801403490600_ejhf3516-bib-0116","first-page":"1246","article-title":"Plakophilin 2 gene therapy prevents and rescues arrhythmogenic rightventricular cardiomyopathy in a mouse model harboring patient genetics","volume":"2","author":"Bradford","year":"2023","journal-title":"NatCardiovasc Res"},{"key":"2026080801403490600_ejhf3516-bib-0117","volume-title":"GeneReviews\u00ae","author":"Taylor","year":"1993"},{"key":"2026080801403490600_ejhf3516-bib-0118","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41586-020-03086-7","article-title":"In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice","volume":"589","author":"Koblan","year":"2021","journal-title":"Nature"},{"key":"2026080801403490600_ejhf3516-bib-0119","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade1633","article-title":"Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy","volume":"14","author":"Nishiyama","year":"2022","journal-title":"Sci Transl Med"},{"key":"2026080801403490600_ejhf3516-bib-0120","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1161\/CIRCRESAHA.120.318674","article-title":"Efficient correction of a hypertrophic cardiomyopathy mutation by ABEmax-NG","volume":"129","author":"Ma","year":"2021","journal-title":"Circ Res"},{"key":"2026080801403490600_ejhf3516-bib-0121","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41591-022-02176-5","article-title":"Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice","volume":"29","author":"Chai","year":"2023","journal-title":"Nat Med"},{"key":"2026080801403490600_ejhf3516-bib-0122","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41591-022-02190-7","article-title":"Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice","volume":"29","author":"Reichart","year":"2023","journal-title":"Nat Med"},{"key":"2026080801403490600_ejhf3516-bib-0123","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg4910","article-title":"Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing","volume":"7","author":"Chemello","year":"2021","journal-title":"Sci Adv"},{"key":"2026080801403490600_ejhf3516-bib-0124","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1089\/scd.2013.0135","article-title":"Exon skipping and gene transfer restore dystrophin expression in human induced pluripotent stem cells-cardiomyocytes harboring DMD mutations","volume":"22","author":"Dick","year":"2013","journal-title":"Stem Cells Dev"},{"key":"2026080801403490600_ejhf3516-bib-0125","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"2026080801403490600_ejhf3516-bib-0126","doi-asserted-by":"crossref","DOI":"10.3390\/genes11050511","article-title":"Efficient generation and correction of mutations in human iPS cells utilizing mRNAs of CRISPR base editors and prime editors","volume":"11","author":"Surun","year":"2020","journal-title":"Genes (Basel)"},{"key":"2026080801403490600_ejhf3516-bib-0127","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1016\/j.cell.2021.09.018","article-title":"Enhanced prime editing systems by manipulating cellular determinants of editing outcomes","volume":"184","author":"Chen","year":"2021","journal-title":"Cell"},{"key":"2026080801403490600_ejhf3516-bib-0128","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-021-01333-6","article-title":"Gene therapy needs a long-term approach","volume":"27","year":"2021","journal-title":"Nat Med"},{"key":"2026080801403490600_ejhf3516-bib-0129","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood.2021014735","article-title":"Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A","volume":"140","author":"Batty","year":"2022","journal-title":"Blood"},{"key":"2026080801403490600_ejhf3516-bib-0130","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/gt.2009.4","article-title":"Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer","volume":"16","author":"Hedman","year":"2009","journal-title":"Gene Ther"},{"key":"2026080801403490600_ejhf3516-bib-0131","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1089\/hum.2012.137","article-title":"Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease","volume":"24","author":"Rosengart","year":"2013","journal-title":"Hum Gene Ther"},{"key":"2026080801403490600_ejhf3516-bib-0132","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41434-021-00295-1","article-title":"Long-term safety and efficacy of intramyocardial adenovirus-mediated VEGF-D\u0394N\u0394C gene therapy eight-year follow-up of phase I KAT301 study","volume":"29","author":"Leikas","year":"2022","journal-title":"Gene Ther"},{"key":"2026080801403490600_ejhf3516-bib-0133","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/dmd.121.000418","article-title":"Adverse drug reactions and toxicity of the Food and Drug Administration-approved antisense oligonucleotide drugs","volume":"50","author":"Alhamadani","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"2026080801403490600_ejhf3516-bib-0134","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1006304","article-title":"A perspective on oligonucleotide therapy: Approaches to patient customization","volume":"13","author":"Thakur","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026080801403490600_ejhf3516-bib-0135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front Immunol"},{"key":"2026080801403490600_ejhf3516-bib-0136","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.addr.2021.01.017","article-title":"Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic\/pharmacodynamic (PK\/PD) models","volume":"170","author":"Chowdhury","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"2026080801403490600_ejhf3516-bib-0137","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143780","article-title":"Overcoming innate immune barriers that impede AAV gene therapy vectors","volume":"131","author":"Muhuri","year":"2021","journal-title":"J Clin Invest"},{"key":"2026080801403490600_ejhf3516-bib-0138","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12951-024-02485-6","article-title":"Engineered nanoparticles promote cardiac tropism of AAV vectors","volume":"22","author":"Switala","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"2026080801403490600_ejhf3516-bib-0139","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1093\/cvr\/cvy300","article-title":"Challenges and advances of CRISPR-Cas9 genome editing in therapeutics","volume":"115","author":"Stellos","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2026080801403490600_ejhf3516-bib-0140","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.37","article-title":"Off-target effects in CRISPR\/Cas9-mediated genome engineering","volume":"4","author":"Zhang","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026080801403490600_ejhf3516-bib-0141","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41392-024-01905-1","article-title":"In vivo evaluation of guide-free Cas9-induced safety risks in a pig model","volume":"9","author":"Ge","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026080801403490600_ejhf3516-bib-0142","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nbt.3437","article-title":"Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9","volume":"34","author":"Doench","year":"2016","journal-title":"Nat Biotechnol"},{"key":"2026080801403490600_ejhf3516-bib-0143","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071608","article-title":"Latest developed strategies to minimize the off-target effects in CRISPR-Cas-mediated genome editing","volume":"9","author":"Naeem","year":"2020","journal-title":"Cells"},{"key":"2026080801403490600_ejhf3516-bib-0144","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/mt.2016.172","article-title":"A self-restricted CRISPR system to reduce off-target effects","volume":"24","author":"Chen","year":"2016","journal-title":"Mol Ther"},{"key":"2026080801403490600_ejhf3516-bib-0145","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature16526","article-title":"High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects","volume":"529","author":"Kleinstiver","year":"2016","journal-title":"Nature"},{"key":"2026080801403490600_ejhf3516-bib-0146","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41551-023-01011-7","article-title":"Optimization of Cas9 activity through the addition of cytosine extensions to single-guide RNAs","volume":"7","author":"Kawamata","year":"2023","journal-title":"Nat Biomed Eng"},{"key":"2026080801403490600_ejhf3516-bib-0147","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","article-title":"CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response","volume":"24","author":"Haapaniemi","year":"2018","journal-title":"Nat Med"},{"key":"2026080801403490600_ejhf3516-bib-0148","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat Biotechnol"},{"key":"2026080801403490600_ejhf3516-bib-0149","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41591-018-0050-6","article-title":"p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells","volume":"24","author":"Ihry","year":"2018","journal-title":"Nat Med"},{"key":"2026080801403490600_ejhf3516-bib-0150","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.cell.2020.10.025","article-title":"Allele-specific chromosome removal after Cas9 cleavage in human embryos","volume":"183","author":"Zuccaro","year":"2020","journal-title":"Cell"},{"key":"2026080801403490600_ejhf3516-bib-0151","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1143157","article-title":"Off-target effects in CRISPR\/Cas9 gene editing","volume":"11","author":"Guo","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"key":"2026080801403490600_ejhf3516-bib-0152","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1038\/s41467-019-12449-2","article-title":"High levels of AAV vector integration into CRISPR-induced DNA breaks","volume":"10","author":"Hanlon","year":"2019","journal-title":"Nat Commun"},{"key":"2026080801403490600_ejhf3516-bib-0153","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkz093","article-title":"Delivering SaCas9 mRNA by lentivirus-like bionanoparticles for transient expression and efficient genome editing","volume":"47","author":"Lu","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2026080801403490600_ejhf3516-bib-0154","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nbt.3081","article-title":"Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo","volume":"33","author":"Zuris","year":"2015","journal-title":"Nat Biotechnol"},{"key":"2026080801403490600_ejhf3516-bib-0155","volume-title":"Gene, Cell & RNA Therapy Landscape Report - Q2 2023 Quarterly Data Report","author":"American Society of Gene + Cell Therapy","year":"2023"},{"key":"2026080801403490600_ejhf3516-bib-0156","volume-title":"Cellular & Gene Therapy Guidances","author":"U.S. Food and Drug Administration"},{"key":"2026080801403490600_ejhf3516-bib-0157","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1038\/d41586-018-07641-1","article-title":"Regulating the gene-therapy revolution","volume":"564","author":"Bender","year":"2018","journal-title":"Nature"},{"key":"2026080801403490600_ejhf3516-bib-0158","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/cvr\/cvab075","article-title":"Alternative strategies in cardiac preclinical research and new clinical trial formats","volume":"118","author":"Kreutzer","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2026080801403490600_ejhf3516-bib-0159","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1006\/mthe.1999.0015","article-title":"Changing roles for academia and industry in genetics and gene therapy","volume":"1","author":"Friedmann","year":"2000","journal-title":"Mol Ther"},{"key":"2026080801403490600_ejhf3516-bib-0160","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/cvr\/cvu057","article-title":"Extra- and intracellular factors regulating cardiomyocyte proliferation in postnatal life","volume":"102","author":"Zacchigna","year":"2014","journal-title":"Cardiovasc Res"},{"key":"2026080801403490600_ejhf3516-bib-0161","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1016\/j.ymthe.2022.09.015","article-title":"AAV vectors: The Rubik's cube of human gene therapy","volume":"30","author":"Pupo","year":"2022","journal-title":"Mol Ther"},{"key":"2026080801403490600_ejhf3516-bib-0162","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.addr.2020.06.005","article-title":"Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers","volume":"157","author":"Fang","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"2026080801403490600_ejhf3516-bib-0163","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/978-1-4939-6588-5_18","article-title":"Selective pressure-regulated retroinfusion for gene therapy application in ischemic heart disease","volume":"1521","author":"Hinkel","year":"2017","journal-title":"Methods Mol Biol"},{"key":"2026080801403490600_ejhf3516-bib-0164","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.833335","article-title":"Targeted delivery for cardiac regeneration: Comparison of intra-coronary infusion and intra-myocardial injection in porcine hearts","volume":"9","author":"Vekstein","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026080801403490600_ejhf3516-bib-0165","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.jacc.2016.02.049","article-title":"Intratracheal gene delivery of SERCA2a ameliorates chronic post-capillary pulmonary hypertension: a large animal model","volume":"67","author":"Aguero","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026080801403490600_ejhf3516-bib-0166","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens12111301","article-title":"Transcriptional targeting approaches in cardiac gene transfer using AAV vectors","volume":"12","author":"Schroder","year":"2023","journal-title":"Pathogens"},{"key":"2026080801403490600_ejhf3516-bib-0167","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101277","article-title":"Cardiac gene delivery using ultrasound: State of the field","volume":"32","author":"Singh","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2026080801403490600_ejhf3516-bib-0168","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1126\/science.aax7063","article-title":"A cytosine deaminase for programmable single-base RNA editing","volume":"365","author":"Abudayyeh","year":"2019","journal-title":"Science"},{"key":"2026080801403490600_ejhf3516-bib-0169","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10557-022-07391-3","article-title":"RNA editing therapeutics: Advances, challenges and perspectives on combating heart disease","volume":"37","author":"Birgaoanu","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026080801403490600_ejhf3516-bib-0170","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1126\/science.aaq0180","article-title":"RNA editing with CRISPR-Cas13","volume":"358","author":"Cox","year":"2017","journal-title":"Science"},{"key":"2026080801403490600_ejhf3516-bib-0171","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41569-022-00804-8","article-title":"RNA modifications in cardiovascular health and disease","volume":"20","author":"Gatsiou","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2026080801403490600_ejhf3516-bib-0172","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2023.03.021","article-title":"The RNA editor ADAR2 promotes immune cell trafficking by enhancing endothelial responses to interleukin-6 during sterile inflammation","volume":"56","author":"Gatsiou","year":"2023","journal-title":"Immunity"},{"key":"2026080801403490600_ejhf3516-bib-0173","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/s41589-019-0327-1","article-title":"Programmable RNA N6-methyladenosine editing by CRISPR-Cas9 conjugates","volume":"15","author":"Liu","year":"2019","journal-title":"Nat Chem Biol"},{"key":"2026080801403490600_ejhf3516-bib-0174","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.cell.2019.05.049","article-title":"Programmable RNA-guided RNA effector proteins built from human parts","volume":"178","author":"Rauch","year":"2019","journal-title":"Cell"},{"key":"2026080801403490600_ejhf3516-bib-0175","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41587-019-0013-6","article-title":"Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides","volume":"37","author":"Merkle","year":"2019","journal-title":"Nat Biotechnol"},{"key":"2026080801403490600_ejhf3516-bib-0176","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41587-019-0178-z","article-title":"Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs","volume":"37","author":"Qu","year":"2019","journal-title":"Nat Biotechnol"},{"key":"2026080801403490600_ejhf3516-bib-0177","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.omtn.2019.12.042","article-title":"Novel engineered programmable systems for ADAR-mediated RNA editing","volume":"19","author":"Aquino-Jarquin","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026080801403490600_ejhf3516-bib-0178","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1038\/s41591-023-02494-2","article-title":"RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: Phase 1 basket trial cohorts","volume":"29","author":"Watts","year":"2023","journal-title":"Nat Med"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/1\/5\/65346904\/eurjhf_27_1_5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/1\/5\/65346904\/eurjhf_27_1_5.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T05:41:06Z","timestamp":1786167666000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/27\/1\/5\/8322630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":178,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,11,22]]},"published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3516","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,11,22]]},"assertion":[{"value":"2024-05-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}